Danish BioTech Samplix secures €25 million in first close of financing round to scale antibody discovery
Samplix, a Danish BioTech company developing droplet microfluidics technology for functional single-cell analysis, has announced a €25 million first closing of a financing round. The financing comprises €3 million in new capital and €22 million in shareholder convertible bonds. It was led by WLanho
<p>Samplix, a Danish BioTech company developing droplet microfluidics technology for functional single-cell analysis, has announced a €25 million first closing of a financing round. The financing comprises €3 million in new capital and €22 million in shareholder convertible bonds. It was led by WLanho</p>